SG11201407200TA - Liquid formulation - Google Patents
Liquid formulationInfo
- Publication number
- SG11201407200TA SG11201407200TA SG11201407200TA SG11201407200TA SG11201407200TA SG 11201407200T A SG11201407200T A SG 11201407200TA SG 11201407200T A SG11201407200T A SG 11201407200TA SG 11201407200T A SG11201407200T A SG 11201407200TA SG 11201407200T A SG11201407200T A SG 11201407200TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new south
- south wales
- suite
- liquid formulation
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000005541 ACE inhibitor Substances 0.000 abstract 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 abstract 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 2
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000005070 sampling Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/170317 A1 (51) International Patent Classification: A61K 47/10 (2006.01) A61K 9/08 (2006.01) A61K31/4184 (2006.01) A61P 9/10 (2006.01) A61K 31/401 (2006.01) (21) International Application Number: PCT/AU2013/000522 (22) International Filing Date: 17 May 2013 (17.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2012902062 18 May 2012 (18.05.2012) AU (71) Applicant: LUODA PHARMA PTY LTD [AU/AU]; Suite 1, 304-318 The Kingsway, Caringbah, New South Wales 2229 (AU). (72) Inventors: BOVA, Nicholas; Suite 1, 304-318 The King- sway, Caringbah, New South Wales 2229 (AU). PAGE, Stephen; 55 Campbell Street, Newtown, New South Wales 2042 (AU). PIPPIA, Giuseppe; Suite 3.501, Level 3, 126 Greville Street, Chatswood West, New South Wales 2067 (AU). (74) Agent: GRIFFITH HACK; GPO Box 4164, Sydney, New South Wales 2001 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: LIQUID FORMULATION Figure 1 l> T-H m o i> 12 3 4 Sampling time post-treatment (hours) • Example 2 - IVP Example 2 - RVP i-H (57) Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, O an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to CJ use of the formulation for treating cardiac disease and/or hypertension.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902062A AU2012902062A0 (en) | 2012-05-18 | Liquid Formulation | |
| PCT/AU2013/000522 WO2013170317A1 (en) | 2012-05-18 | 2013-05-17 | Liquid formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407200TA true SG11201407200TA (en) | 2014-12-30 |
Family
ID=49582909
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201609364QA SG10201609364QA (en) | 2012-05-18 | 2013-05-17 | Liquid formulation |
| SG11201407200TA SG11201407200TA (en) | 2012-05-18 | 2013-05-17 | Liquid formulation |
| SG10201703789QA SG10201703789QA (en) | 2012-05-18 | 2013-05-17 | Liquid formulation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201609364QA SG10201609364QA (en) | 2012-05-18 | 2013-05-17 | Liquid formulation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201703789QA SG10201703789QA (en) | 2012-05-18 | 2013-05-17 | Liquid formulation |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9808529B2 (en) |
| EP (2) | EP2849792B1 (en) |
| JP (2) | JP2015516441A (en) |
| KR (1) | KR102041654B1 (en) |
| CN (2) | CN109568253B (en) |
| AU (1) | AU2013262438B2 (en) |
| BR (1) | BR112014028602B1 (en) |
| CA (1) | CA2873502C (en) |
| CL (1) | CL2014003121A1 (en) |
| CO (1) | CO7160059A2 (en) |
| HK (1) | HK1208372A1 (en) |
| IN (1) | IN2014MN02271A (en) |
| MX (1) | MX369832B (en) |
| NZ (2) | NZ724002A (en) |
| RU (1) | RU2640023C2 (en) |
| SG (3) | SG10201609364QA (en) |
| WO (1) | WO2013170317A1 (en) |
| ZA (1) | ZA201409269B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP3167876B1 (en) | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| CN109568253B (en) | 2012-05-18 | 2022-04-26 | 罗达制药有限公司 | Liquid preparation |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| KR102455648B1 (en) | 2013-07-19 | 2022-10-19 | 베링거잉겔하임베트메디카게엠베하 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| EA201992230A1 (en) | 2013-12-04 | 2020-02-28 | Бёрингер Ингельхайм Ветмедика Гмбх | IMPROVED PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN |
| CN104161756B (en) * | 2014-06-13 | 2017-02-01 | 河北智同医药控股集团有限公司 | Olprinone hydrochloride injection composition |
| JP6861634B2 (en) | 2015-03-03 | 2021-04-21 | イー，リチャード，ダブリュ． | Compositions and Methods for Treating Eye Diseases |
| CN105029678A (en) * | 2015-07-24 | 2015-11-11 | 广东中烟工业有限责任公司 | Tobacco composite additive and application thereof |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| CN106729723A (en) * | 2016-11-21 | 2017-05-31 | 青岛农业大学 | A kind of pharmaceutical composition containing UD-CG115BS.acardi and preparation method thereof |
| AU2018253371B2 (en) * | 2017-04-11 | 2023-10-19 | Ceva Sante Animale | Method for the treatment of heart disease in mammals |
| US10954115B2 (en) * | 2017-12-18 | 2021-03-23 | Maxum Enterprises, Llc | System and method for delivering fuel |
| FR3077984B1 (en) * | 2018-02-16 | 2020-02-21 | Vetoquinol Sa | MULTI-PURPOSE COMPOSITION OF TORASEMIDE |
| AU2020214314A1 (en) * | 2019-01-31 | 2021-08-19 | Scpharmaceuticals Inc. | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
| BR112021023710A2 (en) * | 2019-05-28 | 2022-04-12 | Janssen Sciences Ireland Unlimited Co | Diazepinone derivatives as modulators of capsid assembly |
| CN111803468B (en) * | 2020-06-23 | 2022-12-23 | 黑龙江天龙药业有限公司 | Nasal cavity film spraying agent for targeting, slow-release, film-forming and virus and bacteria inhibiting and preparation method thereof |
| KR102663470B1 (en) | 2023-03-16 | 2024-05-10 | 주식회사 케어사이드 | Composition for prevention of heart disease by pulmonary hypertension and treatment of heart function and functional formulation comprising the same |
| CN117538462B (en) * | 2024-01-10 | 2024-03-26 | 地奥集团成都药业股份有限公司 | Method for detecting related substances of amlodipine benazepril capsules |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05262650A (en) | 1992-03-18 | 1993-10-12 | Meiji Seika Kaisha Ltd | Stable composition for injection |
| IL110752A (en) * | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| GB9717444D0 (en) * | 1997-08-19 | 1997-10-22 | Glaxo Group Ltd | Pharmaceutical composition |
| FI109659B (en) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Pharmaceutical solutions of levosimendan |
| KR100452972B1 (en) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | Hydrogel composition for transdermal drug |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6706563B2 (en) | 2002-04-10 | 2004-03-16 | St Assembly Test Services Pte Ltd | Heat spreader interconnect methodology for thermally enhanced PBGA packages |
| WO2004071490A1 (en) | 2003-02-12 | 2004-08-26 | R & P Korea Co., Ltd. | Solvent system of hardly soluble drug with improved elution rate |
| HUP0300985A2 (en) * | 2003-04-15 | 2005-07-28 | SynoSens Kutató és Fejlesztő Kft. | Pharmaceutical composition having improved spectrum |
| US9259390B2 (en) * | 2003-08-13 | 2016-02-16 | The University Of Houston System | Parenteral and oral formulations of benzimidazoles |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US20060099230A1 (en) * | 2004-11-10 | 2006-05-11 | Chin-Chih Chiang | Novel formulations of eprosartan with enhanced bioavailability |
| KR20080016527A (en) * | 2005-01-31 | 2008-02-21 | 밀란 래보러토리즈, 인크. | Pharmaceutical Compositions Containing Hydroxylated Nebivolol |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| KR20080073700A (en) * | 2005-12-06 | 2008-08-11 | 와이어쓰 | Benzimidazole Non-Aqueous Composition |
| JP4572300B2 (en) * | 2006-01-19 | 2010-11-04 | トーアエイヨー株式会社 | Pimobendan oral dosage formulation |
| KR20070076769A (en) * | 2006-01-20 | 2007-07-25 | 일양약품주식회사 | Injectable composition of amlodipine and preparation method thereof |
| EP1908469A1 (en) * | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| JP2010514778A (en) | 2006-12-28 | 2010-05-06 | オリオン コーポレーション | Levosimendan formulation for parenteral administration |
| WO2009061529A1 (en) | 2007-11-06 | 2009-05-14 | Tap Pharmaceutical Products, Inc. | (+)-enantiomer of 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole and processing method eor preparing the same |
| US20090270356A1 (en) * | 2008-04-28 | 2009-10-29 | Ceva Sante Animale Sa | Compositions and treatments of heart failure in non-human mammal animals |
| AU2010201490C1 (en) * | 2009-04-15 | 2014-07-24 | Zoetis Services Llc | Anthelmintic formulation |
| JP2011006380A (en) | 2009-05-22 | 2011-01-13 | Mochida Pharmaceut Co Ltd | EMULSIFIED COMPOSITION OF ω3 FATTY ACID |
| NL2006622C2 (en) * | 2011-04-18 | 2012-10-22 | Eurovet Animal Health B V | Use of a composition comprising torasemide. |
| CN109568253B (en) | 2012-05-18 | 2022-04-26 | 罗达制药有限公司 | Liquid preparation |
-
2013
- 2013-05-17 CN CN201811478216.3A patent/CN109568253B/en active Active
- 2013-05-17 NZ NZ724002A patent/NZ724002A/en unknown
- 2013-05-17 SG SG10201609364QA patent/SG10201609364QA/en unknown
- 2013-05-17 CA CA2873502A patent/CA2873502C/en active Active
- 2013-05-17 MX MX2014013871A patent/MX369832B/en active IP Right Grant
- 2013-05-17 CN CN201380038290.2A patent/CN104619345A/en active Pending
- 2013-05-17 SG SG11201407200TA patent/SG11201407200TA/en unknown
- 2013-05-17 EP EP13791455.2A patent/EP2849792B1/en active Active
- 2013-05-17 SG SG10201703789QA patent/SG10201703789QA/en unknown
- 2013-05-17 JP JP2015511866A patent/JP2015516441A/en active Pending
- 2013-05-17 WO PCT/AU2013/000522 patent/WO2013170317A1/en active Application Filing
- 2013-05-17 RU RU2014145136A patent/RU2640023C2/en active
- 2013-05-17 US US14/401,943 patent/US9808529B2/en active Active
- 2013-05-17 IN IN2271MUN2014 patent/IN2014MN02271A/en unknown
- 2013-05-17 NZ NZ701609A patent/NZ701609A/en unknown
- 2013-05-17 KR KR1020147035546A patent/KR102041654B1/en active IP Right Grant
- 2013-05-17 BR BR112014028602-7A patent/BR112014028602B1/en active IP Right Grant
- 2013-05-17 EP EP20160396.6A patent/EP3682902A1/en active Pending
- 2013-05-17 AU AU2013262438A patent/AU2013262438B2/en active Active
-
2014
- 2014-11-17 CL CL2014003121A patent/CL2014003121A1/en unknown
- 2014-12-17 ZA ZA2014/09269A patent/ZA201409269B/en unknown
- 2014-12-17 CO CO14277303A patent/CO7160059A2/en unknown
-
2015
- 2015-09-18 HK HK15109160.8A patent/HK1208372A1/en unknown
-
2016
- 2016-11-10 JP JP2016219381A patent/JP6448001B2/en active Active
-
2017
- 2017-10-05 US US15/725,798 patent/US10413610B2/en active Active
-
2019
- 2019-08-16 US US16/542,518 patent/US11357855B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407200TA (en) | Liquid formulation | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408069XA (en) | Hair styling device | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201407747QA (en) | A method and apparatus for facilitating the management of health and security | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia | |
| SG11201406745VA (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs | |
| SG11201810974QA (en) | Methods and compositions for prostate cancer diagnosis and treatment | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201407208UA (en) | A method for dynamic generation and modification of an electronic entity architecture | |
| SG11201901449XA (en) | Method for treating pruritus and/or itch | |
| SG11201809541UA (en) | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |